Fig. 4: Hederagenin promoted the anticancer actions of paclitaxel. | Cell Death & Disease

Fig. 4: Hederagenin promoted the anticancer actions of paclitaxel.

From: Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells

Fig. 4

a NCI-H1299 cells and NCI-H1975 responded to paclitaxel differently under the light microscopy. Scale bar, 50 μm. b NCI-1975 cells were sensitive to paclitaxel treatment. The IC50 for and NCI-H1299 cells and NCI-H1975 cells were 101.4 nM and 22.61 nM, respectively. c Paclitaxel treatment induced autophagy in NCI-H1299 cells but not in NCI-H1975 cells as indicated by LC3 immunoblotting. d & e Hederagenin significantly synergized paclitaxel-induced growth inhibition in NCI-H1299 cells, but not in NCI-H1975 cells. f & g A combination of hederagenin and paclitaxel caused a significantly higher apoptosis rate in NCI-H1299 cells with a Q value of 1.97. ***p < 0.001, ANOVA with multiple comparisons. h Pre-treatment with hederagenin promoted paclitaxel-triggered Caspase-3 and PARP cleavage. Compared with single reagent treatment, the LC3-II level was further upregulated by hederagenin and paclitaxel co-treatment. I A combination of hederagenin and paclitaxel resulted in a significantly higher number of GFP-LC3 puncta than a single drug treatment group (n = 20 cells/group). *p < 0.05, **p < 0.01,***p < 0.001, ANOVA with multiple comparisons. Scale bar, 5 μm. Paclitaxel: PTX, hederagenin: Hed.

Back to article page